Glaukos Research and Development Expenses 2014-2024 | GKOS

Glaukos research and development expenses for the twelve months ending June 30, 2024 were $0.147B, a 7.83% increase year-over-year.

  • Glaukos annual research and development expenses for 2023 were $0.139B, a 12.57% increase from 2022.
  • Glaukos annual research and development expenses for 2022 were $0.123B, a 22.05% increase from 2021.
  • Glaukos annual research and development expenses for 2021 were $0.101B, a 18.28% increase from 2020.

Glaukos Research and Development Expenses 2014-2024 | GKOS

  • Glaukos annual research and development expenses for 2023 were $0.139B, a 12.57% increase from 2022.
  • Glaukos annual research and development expenses for 2022 were $0.123B, a 22.05% increase from 2021.
  • Glaukos annual research and development expenses for 2021 were $0.101B, a 18.28% increase from 2020.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$233.2B
Intuitive Surgical (ISRG)$171.7B
Alcon (ALC)$47.9B
IQVIA Holdings (IQV)$43.7B
IDEXX Laboratories (IDXX)$42.2B
Edwards Lifesciences (EW)$40.5B
DexCom (DXCM)$27.6B
STERIS (STE)$23.8B
SONOVA HOLDING (SONVY)$21.2B
Waters (WAT)$19.5B
Hologic (HOLX)$19B
Sysmex ADR (SSMXY)$12.6B
Fresenius Medical Care AG KGaA (FMS)$12.3B
Teleflex (TFX)$11.4B
Globus Medical (GMED)$9.4B
Penumbra (PEN)$7.3B
Masimo (MASI)$6.1B
TransMedics (TMDX)$5.2B
Integer Holdings (ITGR)$4.2B
PROCEPT BioRobotics (PRCT)$4.1B
Tandem Diabetes Care (TNDM)$2.8B
LivaNova (LIVN)$2.8B
Veracyte (VCYT)$2.6B
Inari Medical (NARI)$2.6B
Elekta AB (EKTAY)$2.5B
Nihon Kohden (NHNKY)$2.5B
RxSight (RXST)$2.1B
Integra LifeSciences Holdings (IART)$1.3B
Pulse Biosciences (PLSE)$1.2B
OPKO Health (OPK)$1.2B